MedPath

To compare the effects of oral tofacitinib plus oral puvasol with oral corticosteroids plus oral puvasol in vitiligo patients and also study the side effects of bothe drugs

Phase 4
Conditions
Health Condition 1: L80- Vitiligo
Registration Number
CTRI/2024/06/069125
Lead Sponsor
SUPRIYA BEHERA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Age more than 18 years

2. Body surface area less than 80%

3. Progressive disease( peak of incidence within 6 months )

Exclusion Criteria

1. Universal vitiligo

2. Pregnant and lactating women

3. Patients undergoing immunosuppressive therapy

4. Patients of leukoderma due to other causes

5. Patients having photosensitivity

6. Patients having malignancy or undergone radiotherapy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath